CL2019003239A1 - Amidas de piridona deuteradas y profármacos de los mismos como moduladores de canales de sodio. - Google Patents
Amidas de piridona deuteradas y profármacos de los mismos como moduladores de canales de sodio.Info
- Publication number
- CL2019003239A1 CL2019003239A1 CL2019003239A CL2019003239A CL2019003239A1 CL 2019003239 A1 CL2019003239 A1 CL 2019003239A1 CL 2019003239 A CL2019003239 A CL 2019003239A CL 2019003239 A CL2019003239 A CL 2019003239A CL 2019003239 A1 CL2019003239 A1 CL 2019003239A1
- Authority
- CL
- Chile
- Prior art keywords
- sodium channels
- deuterated
- prodrugs
- modulators
- compounds
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title abstract 2
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- -1 Deuterated pyridone amides Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507172P | 2017-05-16 | 2017-05-16 | |
| US201762547718P | 2017-08-18 | 2017-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003239A1 true CL2019003239A1 (es) | 2020-04-17 |
Family
ID=62567801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003239A CL2019003239A1 (es) | 2017-05-16 | 2019-11-12 | Amidas de piridona deuteradas y profármacos de los mismos como moduladores de canales de sodio. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11358977B2 (enExample) |
| EP (1) | EP3625214B1 (enExample) |
| JP (1) | JP7104070B2 (enExample) |
| KR (1) | KR102714561B1 (enExample) |
| CN (1) | CN110740993B (enExample) |
| AU (1) | AU2018271110A1 (enExample) |
| BR (1) | BR112019024016A2 (enExample) |
| CA (1) | CA3063901A1 (enExample) |
| CL (1) | CL2019003239A1 (enExample) |
| CO (1) | CO2019013021A2 (enExample) |
| ES (1) | ES2927712T3 (enExample) |
| IL (1) | IL270680B (enExample) |
| MA (1) | MA49137A (enExample) |
| MX (1) | MX390793B (enExample) |
| UA (1) | UA124857C2 (enExample) |
| WO (1) | WO2018213426A1 (enExample) |
| ZA (1) | ZA201907619B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| AR116939A1 (es) | 2018-11-02 | 2021-06-30 | Merck Sharp & Dohme | 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8 |
| AU2020205139A1 (en) * | 2019-01-04 | 2021-08-19 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020151728A1 (zh) * | 2019-01-25 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| AU2020224245A1 (en) * | 2019-02-20 | 2021-08-05 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine |
| WO2020206119A1 (en) * | 2019-04-02 | 2020-10-08 | Vertex Pharmaceuticals Incorporated | Process for making pyridone amides and prodrugs thereof useful as modulators of sodium channels |
| WO2020219867A1 (en) * | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| ES2991171T3 (es) * | 2019-07-16 | 2024-12-02 | Bristol Myers Squibb Co | Profármacos en la modulación de la interleucina |
| WO2021018165A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| TW202115038A (zh) * | 2019-08-19 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用 |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| MX2022015581A (es) | 2020-06-17 | 2023-01-24 | Merck Sharp & Dohme Llc | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| WO2022037647A1 (zh) * | 2020-08-19 | 2022-02-24 | 江苏恒瑞医药股份有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| TW202214259A (zh) * | 2020-08-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種選擇性ＮａＶ抑制劑的前藥及其晶型 |
| CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| EP4262978A1 (en) * | 2020-12-18 | 2023-10-25 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
| TW202239409A (zh) * | 2020-12-18 | 2022-10-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| TW202302118A (zh) * | 2021-02-26 | 2023-01-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種選擇性ｎａｖ抑制劑的可藥用鹽、結晶形式及其製備方法 |
| TWI827037B (zh) | 2021-05-07 | 2023-12-21 | 美商默沙東有限責任公司 | 作為nav1.8抑制劑之環烷基3-側氧基哌甲醯胺及環雜烷基3-側氧基哌甲醯胺 |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| BR112023025264A2 (pt) | 2021-06-04 | 2024-02-20 | Vertex Pharma | Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida |
| JP2024520648A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド |
| UY39882A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| UY39881A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS” |
| WO2023081188A1 (en) * | 2021-11-02 | 2023-05-11 | Schedule 1 Therapeutics, Inc. | Use of cannabinoid compositions for treating pain associated with small fiber neuropathy |
| CA3256604A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| EP4511117A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| JP2025513454A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| GEAP202516632A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
| CN120603815A (zh) | 2022-12-06 | 2025-09-05 | 沃泰克斯药物股份有限公司 | 钠通道的取代四氢呋喃调节剂的合成方法 |
| WO2024159285A1 (pt) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| AR131658A1 (es) | 2023-01-30 | 2025-04-16 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits |
| AR131690A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS |
| AR131715A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS |
| WO2024159287A1 (pt) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Hidroxamatos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DE60001623T2 (de) * | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| WO2002008748A2 (en) | 2000-07-10 | 2002-01-31 | Aurora Biosciences Corporation | Ion channel assay methods |
| JP2003034671A (ja) | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法 |
| DE60330126D1 (de) | 2002-02-14 | 2009-12-31 | Pharmacia Corp | Substituierte pyridinone als modulatoren für p38 map kinase |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| AU2004263179B8 (en) | 2003-08-08 | 2011-07-14 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| JP4056081B1 (ja) | 2004-07-23 | 2008-03-05 | ファイザー・インク | ピリジン誘導体 |
| BRPI0617987A2 (pt) * | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| US8841483B2 (en) | 2006-04-11 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| MX2009003876A (es) | 2006-10-12 | 2009-05-11 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos. |
| AU2008247102B2 (en) | 2007-05-03 | 2011-11-24 | Pfizer Limited | 2 -pyridine carboxamide derivatives as sodium channel modulators |
| CN101855210A (zh) | 2007-10-11 | 2010-10-06 | 沃泰克斯药物股份有限公司 | 用作电压-门控钠通道抑制剂的酰胺类 |
| US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| NZ584519A (en) | 2007-10-11 | 2012-07-27 | Vertex Pharma | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| EP2356094A1 (en) | 2008-10-29 | 2011-08-17 | F. Hoffmann-La Roche AG | Novel phenyl amide or pyridil amide derivatives and their use as gpbar1 agonists |
| BRPI0924059A2 (pt) | 2008-12-23 | 2015-07-07 | Hoffmann La Roche | Didro piridona amidas como moduladores de p2x7 |
| TWI436986B (zh) | 2008-12-26 | 2014-05-11 | Dainippon Sumitomo Pharma Co | 新穎之２環性雜環化合物 |
| CN102448937A (zh) | 2009-05-29 | 2012-05-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011026240A1 (en) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| CN103429571A (zh) | 2010-12-22 | 2013-12-04 | 普渡制药公司 | 作为钠通道阻断剂的取代吡啶 |
| RU2634900C2 (ru) | 2011-02-02 | 2017-11-08 | Вертекс Фармасьютикалз Инкорпорейтед | Спироциклические пирролопиразин(пиперидин)амиды в качестве модуляторов ионных каналов |
| JP5940562B2 (ja) | 2011-02-18 | 2016-06-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド |
| EP3009427B1 (en) | 2011-03-03 | 2019-12-18 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| EP2680843A4 (en) | 2011-03-03 | 2015-05-06 | Concert Pharmaceuticals Inc | DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS |
| WO2012125613A1 (en) | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| RS56342B1 (sr) | 2011-09-02 | 2017-12-29 | Purdue Pharma Lp | Pirimidini kao blokatori natrijumskog kanala |
| CN103906746B (zh) | 2011-10-26 | 2015-12-09 | 辉瑞有限公司 | 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 |
| US9403839B2 (en) | 2012-01-16 | 2016-08-02 | Vertex Pharmaceuticals Incorporated | Pyran-spirocyclic piperidine amides as modulators of ion channels |
| EP2809655B1 (en) | 2012-02-03 | 2015-08-12 | Pfizer Inc | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| PT2822953T (pt) | 2012-03-06 | 2017-04-06 | Pfizer | Derivados macrocíclicos para o tratamento de doenças proliferativas |
| BR112015018284B1 (pt) | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| RS56015B1 (sr) | 2013-01-31 | 2017-09-29 | Vertex Pharma | Piridon amidi kao modulatori natrijumovih kanala |
| AR095192A1 (es) | 2013-01-31 | 2015-09-30 | Vertex Pharma | Quinolina y quinazolinamidas como modulares de canales de sodio |
| TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
| CN105683157B (zh) | 2013-07-19 | 2019-07-19 | 沃泰克斯药物股份有限公司 | 用作钠通道调节剂的磺酰胺类 |
| SI3080134T1 (sl) * | 2013-12-13 | 2018-11-30 | Vertex Pharmaceuticals Incorporated | Predzdravila piridon amidov uporabna kot modulatorji natrijevih kanalov |
| JP7277431B2 (ja) | 2017-07-11 | 2023-05-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのカルボキサミド |
| US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
-
2018
- 2018-05-16 US US16/614,015 patent/US11358977B2/en active Active
- 2018-05-16 BR BR112019024016A patent/BR112019024016A2/pt active Search and Examination
- 2018-05-16 IL IL270680A patent/IL270680B/en unknown
- 2018-05-16 MX MX2019013574A patent/MX390793B/es unknown
- 2018-05-16 AU AU2018271110A patent/AU2018271110A1/en not_active Abandoned
- 2018-05-16 CA CA3063901A patent/CA3063901A1/en active Pending
- 2018-05-16 EP EP18730543.8A patent/EP3625214B1/en active Active
- 2018-05-16 MA MA049137A patent/MA49137A/fr unknown
- 2018-05-16 UA UAA201911875A patent/UA124857C2/uk unknown
- 2018-05-16 WO PCT/US2018/032939 patent/WO2018213426A1/en not_active Ceased
- 2018-05-16 JP JP2019563132A patent/JP7104070B2/ja active Active
- 2018-05-16 KR KR1020197037074A patent/KR102714561B1/ko active Active
- 2018-05-16 ES ES18730543T patent/ES2927712T3/es active Active
- 2018-05-16 CN CN201880037064.5A patent/CN110740993B/zh active Active
-
2019
- 2019-11-12 CL CL2019003239A patent/CL2019003239A1/es unknown
- 2019-11-18 ZA ZA2019/07619A patent/ZA201907619B/en unknown
- 2019-11-21 CO CONC2019/0013021A patent/CO2019013021A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA49137A (fr) | 2021-04-21 |
| KR102714561B1 (ko) | 2024-10-10 |
| MX390793B (es) | 2025-03-21 |
| WO2018213426A1 (en) | 2018-11-22 |
| CN110740993A (zh) | 2020-01-31 |
| ES2927712T3 (es) | 2022-11-10 |
| US11358977B2 (en) | 2022-06-14 |
| EP3625214B1 (en) | 2022-07-06 |
| KR20200006128A (ko) | 2020-01-17 |
| US20210155643A1 (en) | 2021-05-27 |
| IL270680B (en) | 2022-06-01 |
| JP2020519661A (ja) | 2020-07-02 |
| CO2019013021A2 (es) | 2020-04-01 |
| CA3063901A1 (en) | 2018-11-22 |
| UA124857C2 (uk) | 2021-12-01 |
| CN110740993B (zh) | 2023-09-01 |
| ZA201907619B (en) | 2022-03-30 |
| MX2019013574A (es) | 2019-12-18 |
| EP3625214A1 (en) | 2020-03-25 |
| BR112019024016A2 (pt) | 2020-06-09 |
| AU2018271110A1 (en) | 2019-12-05 |
| JP7104070B2 (ja) | 2022-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003239A1 (es) | Amidas de piridona deuteradas y profármacos de los mismos como moduladores de canales de sodio. | |
| ECSP22052564A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
| MX2015009602A (es) | Piridona amidas como moduladores de canales de sodio. | |
| MX2015009591A (es) | Amidas como moduladores de canales de sodio. | |
| JOP20200154A1 (ar) | مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1 | |
| ECSP16025201A (es) | Profármacos de amidas de piridona útiles como moduladores de canales de sodio | |
| UY37845A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| CO7160015A2 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
| ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
| UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
| UY31063A1 (es) | Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones. | |
| CO2022004723A2 (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| MX2017011978A (es) | Analogos deuterados de etifoxina, sus derivados y usos de estos. | |
| EA201992679A1 (ru) | N-замещенные индольные производные | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| BR112020008258B8 (pt) | Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido) | |
| CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| SA521421354B1 (ar) | مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون | |
| MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
| PE20210550A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico |